Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

NICE approves dexamethasone for macular oedema

By News Team

Dexamethasone has been approved in England and Wales for the treatment of patients with macular oedema by the National Institute for Health and Clinical Excellence.

New guidance published this week (27 July 2011) recommends dexamethasone (Ozurdex; Allergan) intravitreal implant injected into the affected eye once every 6 months, for the treatment of macular oedema following central retinal vein occlusion.

The guidance also recommends dexamethasone following branch retinal vein occlusion when treatment with laser photocoagulation has not been beneficial or has not been considered suitable because of the extent of macular haemorrhage.

Although dexamethasone costs more than the current most common treatment bevacizumab, the benefits to vision outweigh the cost, says NICE.

Citation: The Pharmaceutical Journal URI: 11081421

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.